Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis
By Giuseppe Lippi, Mario Plebani, B. Henry. Clinica chimica acta; international journal of clinical chemistry, 2020
1,534 citations recorded by the source corpus.
Highlights • Platelet count can discriminate between severe and non-severe COVID-19 infections.• Patients who did not survive have a significantly lower platelet count than survivors.• Thrombocytopenia is associated with increased risk of severe disease.• A substantial decrease in platelet count may be an indicator of worsening illness.
Subfields: Hematology, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/46890c77cb87c126ce5e54a327d2adfc81b44198
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Infectious Diseases
Citations in the corpus
- Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 (2020, background): “4)* Fibrinogen, mg/dL§ 281 (236-312) 229 (167-324) 545 (375-582)* D-dimer, ng/mL§ 328 (227-456) 192 (190-291) 4 205 (2 319-14 179)* IL-6, pg/mL 9 (7-15) 9 (7.”
- Automatic Detection of Coronavirus Disease (COVID-19) in X-ray and CT Images: A Machine Learning Based Approach (2020, neutral): “The pneumonia was found to be caused by a virus identified as ”severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), with the associated disease subsequently termed coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) [1] [2].”
- Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes (2020, positive): “Additionally, a meta-analysis of nine studies of patients with COVID-19 showed that thrombocytopenia is associated with a 5-fold increased risk of severity and mortality (Lippi et al., 2020).”
- Biomarkers associated with COVID-19 disease progression (2020, background): “Low platelet count has been associated with increased risk of severe disease and mortality for COVID-19 patients, and can serve as an indicator of clinical disease worsening during hospitalization [55].”
- Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis (2020, background): “In earlier reports, we have identified procalcitonin and platelet count as potential predictors of disease severity [2, 3].”
- Proteomic and Metabolomic Characterization of COVID-19 Patient Sera (2020, background): “Low platelet count is also reported to be associated with severe COVID-19 and mortality (Lippi et al., 2020).”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “The most consistent hemostatic abnormalities with COVID-19 include mild thrombocytopenia (22) and increased D-dimer levels (23), which are associated with a higher risk of requiring mechanical ventilation; intensive care unit (ICU) admission; or death (Table 2).”